family with sequence similarity 193 member AGenealiases: C4orf8 · RES4-22
Q-omics provides the consensus-scored FAM193A profile across patient tissues and cancer cell-line models. FAM193A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, FAM193A is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, FAM193A RNA expression shows 21,527 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, KIRC, and ACC as cancer lineages where FAM193A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM193A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM193A survival associations across molecular data types. FAM193A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM193A RNA expression–survival associations across cancer types. High FAM193A expression shows unfavorable associations in ACC, LIHC and KICH, but favorable associations in UCS, HNSC and UCEC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for FAM193A RNA expression.
This table summarizes FAM193A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM193A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM193A shows higher tumor expression in KIRC, LIHC, STAD, CHOL, HNSC and KIRP. The KIRC box plot shows higher FAM193A RNA expression in tumor versus normal tissue (log2 FC = +0.658, t-test p < 0.001).
This table shows molecular features associated with FAM193A in patient tissues and cancer cell lines. In patient samples, FAM193A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM193A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
